Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;328:883-884 (10 April), doi:10.1136/bmj.328.7444.883
Malvinder S Parmar, medical director1
1 Department of Internal Medicine, Timmins and District Hospital, Timmins, ON, Canada P4N 8R1
Correspondence to: M S Parmar, Suite 108, 707 Ross Avenue East, Timmins, ON, Canada P4N 8R1 atbeat{at}ntl.sympatico.ca
The kidney plays an important role in glucose homoeostasis: in addition to metabolising between 30% and 40% of insulin,3 it provides up to 45% of endogenous glucose through gluconeogenesis during a prolonged fast.4 In renal failure, it cannot metabolise insulin or generate glucose, thereby increasing the risk of hypoglycaemia. Hypoglycaemia affects 67% of diabetic patients with renal failure, and in almost half (46%) of patients it is often related to the medication they are taking.5 I present a case where a decline in renal function after treatment with diclofenac resulted in recurrent episodes of hypoglycaemia, highlighting the importance of monitoring renal function in a diabetic patient with new onset hypoglycaemia.
He had started to experience low back pain a month before presentation with his third episode of hypoglycaemia and saw his family doctor, who prescribed diclofenac 50 mg twice daily; his back pain then improved. Two weeks later, he started to experience headache and irritability with periods of sweating. His wife brought him to the emergency department on three occasions16, 19, and 23 days after starting diclofenacand he was noted to be hypoglycaemic with blood glucose concentrations of 1.2-2.5 mmol/l. At each visit his symptoms responded to intravenous glucose and feeding. No investigations were done at his first two visits to the emergency department.
At his third visit, his blood glucose concentration was 1.2 mmol/l. A history taken at this visit after correction of hypoglycaemia was unremarkable. The patient reported no decrease in his appetite or increase in physical activity in the past month and no decrease in urine output. Physical examination was unremarkable, with a blood pressure of 150/90 mm Hg. There was no peripheral oedema. Investigations showed a raised serum creatinine concentration of 440 µmol/l and a raised serum urea concentration of 14.6 mmol/l (1.7-8.3 mmol/l); serum potassium concentration was 4.8 mmol/l (3.5-5.0 mmol/l).
Since starting to take the non-steroidal anti-inflammatory drug diclofenac, the patient had developed a decline in renal function with a fourfold increase in serum creatinine. Diclofenac was immediately stopped and his insulin dosage was decreased. Two weeks later, his serum creatinine concentration returned to baseline and he resumed his usual insulin dosage, with no further episodes of hypoglycaemia and with reasonable glucose control.
In chronic, progressive renal failure the physician is aware of the risk associated with NSAIDs and adjusts the dose of insulin or hypoglycaemic agents accordingly. However, when renal dysfunction is unexpected, a patient with poorly controlled glucose concentrations may notice improvement in glycaemic control or hypoglycaemia because of the decreased requirement for insulin or hypoglycaemic agents, and both the physician and the patient may be pleased with this desired but passive improvement in glycaemic control. In such patients, it is important to check that there has been no recent decline in their renal function.
Contributors: MSP is the sole contributor.
Competing interests: None declared.
Read all Rapid Responses
UK medical students have published unreleased government plans to restrict failed asylum seekers' access to medical care